Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 8/20 | 0.60 |
| ▸ | CCNE1 | P24864 | 8/20 | 0.60 |
| ▸ | CDK2 | P24941 | 8/20 | 0.60 |
| ▸ | ROCK1 | Q13464 | 8/20 | 0.60 |
| ▸ | DBF4 | Q9UBU7 | 8/20 | 0.60 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL613707 | 0.76 | CDC7 (0.72) | CDC7CCNE1CDK2ROCK1DBF4 | |
| SCHEMBL613654 | 0.76 | CDC7 (1.00) | CDC7CCNE1CDK2ROCK1DBF4 | |
| SCHEMBL613694 | 0.63 | CDC7 (0.79) | CDC7CCNE1CDK2ROCK1DBF4 | |
| SCHEMBL611631 | 0.62 | GAA (0.33) | CDC7CCNE1CDK2ROCK1DBF4 | |
| SCHEMBL612582 | 0.62 | CDC7 (0.78) | CDC7CCNE1CDK2ROCK1DBF4 | |
| SCHEMBL17362567 | 0.61 | MKNK1 (0.40) | CDC7CCNE1CDK2ROCK1DBF4 | |
| SCHEMBL612349 | 0.60 | CDC7 (0.54) | CDC7CCNE1CDK2ROCK1DBF4 | |
| SCHEMBL20011063 | 0.57 | MKNK1 (0.56) | CDC7CCNE1CDK2ROCK1DBF4 | |
| SCHEMBL17362613 | 0.57 | MKNK1 (0.56) | CDC7CCNE1CDK2ROCK1DBF4 | |
| SCHEMBL20010696 | 0.56 | MKNK1 (0.41) | CDC7CCNE1CDK2ROCK1DBF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2403857-B1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2013-12-04 | — | — | EP | disclosed |
| US-20120040981-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040981-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | CDC7, CDK7, DTYMK | CDC7 1/4885CCNE1 158/4885CDK2 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.